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Background: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has been intensively studied to
lower low-density lipoprotein cholesterol (LDL-C) levels. The purpose of this meta-analysis was to evaluate the safety
and efficacy of anti-PCSK9 antibodies in randomized, controlled trials (RCTs).
Methods: PubMed, EMBASE, CENTRAL databases, and recent conferences were searched. Safety outcomes were
rates of common adverse events. Efficacy outcomes included percentages of LDL-C lowering and other lipid
changes compared with placebo and ezetimibe, respectively.
Results: Twenty-five RCTs encompassing 12,200 patients were included. The rates of common adverse events were
firstly reported in our study by pooling together all evidence in RCTs, showing largely no significant difference
between anti-PCSK9 antibodies and placebo (or ezetimibe), except that alirocumab was associated with reduced
rates of death (relative risk (RR): 0.43, 95 % confidence interval (CI): 0.19 to 0.96, P = 0.04) and an increased rate of
injection-site reactions (RR: 1.48, 95 % CI: 1.05 to 2.09, P = 0.02); evolocumab reduced the rate of abnormal liver
function (RR: 0.43, 95 % CI: 0.20 to 0.93, P = 0.03), both compared with placebo. No significant difference in safety
outcomes was detected between monthly 420 mg and biweekly 140 mg evolocumab treatments. Monthly 420 mg
evolocumab treatment significantly reduced LDL-C by −54.6 % (95 % CI: −58.7 to −50.5 %) and by absolute −78.9
mg/dl (95 % CI: −88.9 to −68.9 mg/dl) versus placebo, and by −36.3 % (95 % CI: −38.8 to −33.9 %) versus ezetimibe,
and increased high-density lipoprotein cholesterol (HDL-C) by 7.6 % (95 % CI: 5.7 to 9.5 %) versus placebo and
6.4 % (95 % CI: 4.3 to 8.4 %) versus ezetimibe. An equal or even greater change was observed following biweekly
140 mg administration. Significant and favorable changes were also detected in other lipids following evolocumab
treatment. Biweekly 50 to 150 mg alirocumab lowered LDL-C by −52.6 % (95 % CI: −58.2 to −47.0 %) versus placebo,
by −29.9 % (95 % CI: −32.9 to −26.9 %) versus ezetimibe, and increased HDL-C by 8.0 % (95 % CI: 4.2 to 11.7 %) versus
placebo.
Conclusions: Evolocumab and alirocumab were safe and well-tolerated from our most-powered analyses. Both
antibodies substantially reduced the LDL-C level by over 50 %, increased the HDL-C level, and resulted in favorable
changes in other lipids.
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Hypercholesterolemia is a major risk factor for cardiovas-
cular disease (CVD) [1]. The introduction of statins has
substantially reduced CVD events around the world and is
recommended as first-line therapy for CVD management
[2]. However, a necessity for other lipid-lowering (espe-
cially low-density lipoprotein cholesterol (LDL-C) lower-
ing) agents still exists because some patients cannot
tolerate statins due to adverse events, or cannot achieve
intensive LDL-C lowering because of extremely high base-
line LDL-C levels, or patients with very high risk of CVD
events need more intensive lowering therapy [3].
The role of proprotein convertase subtilisin/kexin type
9 (PCSK9) in cholesterol regulation has been established
since PCSK9 mutations were first discovered in auto-
somal dominant hypercholesterolemia (ADH) in 2003
[4]. PCSK9 binds to LDL receptors (LDLR) and facili-
tates the degradation of LDLRs [5] and thus leads to
LDL-C increase, indicating great therapeutic potential.
Therefore, inhibiting PCSK9 by monoclonal antibodies
[6, 7], small interfering RNA [8], and small molecule in-
hibitors [9] has been evaluated to lower LDL-C levels in
human studies during the last few years. However, a
comprehensive analysis of the safety of anti-PCSK9 anti-
bodies is absent, and efficacy outcomes on lipid profiles
are not uniformly consistent. Therefore, we performed a
comprehensive review of the current available evidence
to address the safety (to provide the exact rates of com-
mon adverse events) and the efficacy (to determine the




We sought to identify all randomized, controlled trials
(RCTs) evaluating the safety and efficacy of PCSK9 mono-
clonal antibodies. We searched PubMed, EMBASE, and
the Cochrane Central Register of Controlled Trials (CEN-
TRAL) from their inception to 6 October 2014, using the
following search terms and key words: ‘AMG 145’, ‘evolo-
cumab’, ‘SAR236553’, ‘REGN727x’, ‘SAR236553/REGN727’,
‘alirocumab’ and ‘PCSK9’. Reference lists of the identified
reports and relevant reviews were manually checked.
Major conference proceedings were searched to retrieve
unpublished studies until the end of the American Heart
Association (AHA) scientific sessions on 20 November
2014. We did not apply any restriction on languages.
Study selection
Eligibility assessment was performed by two investiga-
tors (XZ and QZ). Studies were included if they: 1) were
RCTs; 2) involved human subjects; 3) evaluated the
safety and efficacy of an anti-PCSK9 antibody (evolocu-
mab or alirocumab); and 4) reported mean differenceswith corresponding confidence intervals (CIs) or pro-
vided data necessary to calculate such. We did not re-
strict the type of study populations. We excluded animal
studies, studies which were not randomized, and studies
using other anti-PCSK9 antibodies, such as bococizu-
mab, or PCSK9 inhibitors such as small interfering RNA
because of the limited number of trials published regard-
ing these PCSK9 inhibitors.
Outcomes
The safety outcomes were rates of common adverse
events, and the primary efficacy endpoints were percent
and absolute reductions in LDL-C following anti-PCSK9
antibody treatment. Secondary outcomes included: 1)
LDL-C reduction at 52 weeks follow-up for evolocumab;
2) other lipid profile changes stratified by treatment dos-
ages and durations of follow-up.
Data collection
Data were abstracted independently by two reviewers
(XZ and QZ) using a standardized data extraction form.
When there were disagreements, a third reviewer (LZ)
checked the data. The following information was ex-
tracted: trial name/first author, year of publication, num-
ber of patients, duration of follow-up, age, gender, race,
diabetes mellitus, coronary heart disease (CHD), PCSK9
level and all lipid profiles at baseline. Patient profile and
background lipid-lowering therapy, treatments and doses
in each study were also recorded. For safety endpoints,
we extracted the number of events of interest and total
number of patients in each group. For efficacy outcomes,
as a priority, we extracted the mean differences and their
corresponding 95 % CIs or standard errors (SEs) of anti-
PCSK9 antibody versus placebo or ezetimibe for each
lipid items. Alternatively, mean changes and 95 % CIs
(or SEs) from baseline after either anti-PCSK9 antibody
or placebo (or ezetimibe) treatments were extracted,
thereafter mean differences of anti-PCSK9 antibody ver-
sus controls were calculated.
Quality assessment
We followed the Cochrane Collaboration’s tool to assess
the risk of bias of included trials. Random sequence gener-
ation (selection bias), allocation concealment (selection
bias), blinding of participants and personnel (performance
bias), blinding of outcome assessment (detection bias), in-
complete outcome data (attrition bias), selective reporting
(reporting bias) and other sources of bias were included in
the assessment independently performed by two reviewers
(QZ and LZ).
Statistical analysis
For all efficacy outcomes, the mean differences following
anti-PCSK9 treatment versus placebo or ezetimibe were
Fig. 1 Flow diagram for study selection
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random-effects models. Comparisons of anti-PCSK9
antibodies with placebo or ezetimibe were performed
separately and stratified by dosages of antibodies. Ad-
verse event rates were also pooled with random-effects
models. Trials in which the endpoint was not detected
in any of the treatment groups were excluded in the ana-
lysis of that endpoint. For studies in which only one of
the groups had no event of interest, the estimate of
treatment effect and its confidence interval were calcu-
lated after adding 0.5 to each cell of the 2 × 2 table for
the trial [10, 11]. We used the I2 statistic to assess the
consistency across studies, with 25 %, 50 %, and 75 % in-
dicating low, moderate, and high degrees of heterogen-
eity respectively. Meanwhile, the χ2-based Q test was
applied, and a P >0.10 suggests significant heterogeneity.
Begg’s test and Egger’s test were performed to assess pub-
lication bias. Sensitivity analyses were carried out by omit-
ting one study at one time to evaluate the consistency of
the results.
In the LAPLACE-2 trial [7], efficacy data comparing
evolocumab and ezetimibe were only reported in five
subgroups stratified by background lipid-lowering ther-
apies. We combined the results from these subgroups
into a single group using the formulae recommended by
the Cochrane Collaboration [12]. All analyses were con-
ducted with the STATA version 11.0 software (STATA
Corporation, College Station, TX, USA). The meta-
analysis was in line with recommendations from the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement (Additional file 1).
Results
Study selection and characteristics
Our systematic literature search yielded 273 studies.
After excluding duplicate publications and studies which
clearly did not meet the inclusion criteria based on titles
and abstracts, 22 studies were retrieved for full-text re-
view. Six studies were further excluded, in which one
study was not RCT [13] and two were phase 1 trials with
either non-constant dosage of anti-PCSK9 antibodies or
with too few participants [14,15]. Nine additional studies
were identified in the recent conference of the European
Society of Cardiology (ESC) and AHA, and were in-
cluded in the meta-analysis [16-22] (Fig. 1). During the
revision process of this paper, two of the trials (ODYSSEY
LONG TERM and ODYSSEY COMB II trials) included in
our analysis as conference presentations [16, 18] from 2014
AHA and ESC scientific sessions were published [23, 24].
Thus, 25 studies were included, encompassing a total of
12,200 patients. Twelve trials were conducted using
anti-PCSK9 antibody evolocumab (AMG 145) [7, 25–35],
and 13 were on alirocumab (SAR236553/REGN727)
[16–22, 36–39]. The OSLER study was carried out basedon participants from four parent trials (GAUSS, MEN-
DEL, LAPLACE-TIMI 57, and RUTHERFORD) and was
followed up for 52 weeks [30].
Baseline characteristics of individual trials are shown
in Table 1 and Table S1 and S2 (in Additional file 2).
Several studies did not report age, lipids or PCSK9 level
in the overall population. Therefore, we presented these
characteristics in control populations (placebo or ezeti-
mibe) in these studies given the significantly similar
baseline values between the anti-PCSK9 treatment group
and controls. All randomized trials included were pub-
lished or presented in major conferences between 2012
and 2014. The mean age ranged from 31 to 62 years,
and the percentage of women from 37 to 74; over 80 %
of the patients were white. Regarding evolocumab, all
trials were followed up for 12 weeks, except the OSLER
and DESCARTES trials [25, 30], which were followed up
for 52 weeks. With regard to alirocumab, most trials were
followed up for 24 weeks except three phase 2 trials which
were followed-up for 8 to 12 weeks [36, 37, 39]. All in-
cluded RCTs had a low risk of bias, as detailed in Table S3
(in Additional file 2).
Safety outcomes of evolocumab
The pooled estimate for overall incidence of any treat-
ment emergent adverse events (TEAEs) was 52.2 % (95 %
Table 1 Baseline characteristics of included randomized trials


























Patient profile and background
lipid-lowering therapy
RUTHERFORD 2012 167 12 50 (13) 79 (47) 4.0 (1.1) 6.1 (1.3) 1.3 (0.4) 8.3 (2.4) 150 (89) 108 (64) 35 (21) NA HeFH with LDL-C ≥2.6 mmol/L.
Statin ± ezetimibe




LDL-C ≥2.2 mmol/L and
triglycerides ≤4.5 mmol/L. Statin ±
ezetimibe
GAUSS 2012 157 12 62 (8) 100 (64) 5.0 (1.3) 7.3 (1.4) 1.5 (0.5) 5.3 (1.4) 0 64 (40) 21
(13.4)
NA LDL-C ≥2.6 mmol/L with diagnosed
CHD or risk equivalent; ≥3.4 mmol/
L without CHD or risk equivalent
and 2 or more risk factors, or ≥4.1
mmol/L without CHD or risk
equivalent and with 1 or 0 risk
factors. No/low-dose statin or statin-
intolerance
MENDEL 2012 406 12 51 (12) 267 (66) 3.7 (0.6) 5.7 (0.8) 1.4 (0.4) 4.8 (1.2) 0 45 (11) 0 1 (0.2) LDL-C ≥2.6 and <4.9 mmol/L and
triglycerides ≤4.5 mmol/L, and a 10
year Framingham risk score for
coronary heart disease of up to 10
%. No background anti-lipid therapy
YUKAWA 2014 307 12 62 (10) 114 (37) 3.7 (0.5) 5.8 (0.6) 1.4 (0.3) 5.6 (1.8) 307 (100) NA 77 (25) 117
(38)
LDL-C ≥3.0 mmol/L and
triglycerides ≤4.5 mmol/L high risk
for cardiovascular events. Statin ±
ezetimibe
MENDEL-2 2014 614 12 54 (10) 423 (69) 3.6 (0.5) NA 1.5 (1.1, 2.0) 3.9 (1.2) 0 154 (25) 0 1 (0.1) LDL-C ≥2.6 and <4.9 mmol/L,
triglycerides ≤4.5 mmol/L, and 10-
year Framingham coronary heart
disease risk scores ≤ 10 %. No lipid
regulating drugs within 3 months




LDL-C ≥3.9 mmol/L (no statin at
screening), ≥2.6 mmol/L
(nonintensive statin at screening), or
≥2.1 mmol/L (intensive statin at
screening) and triglyceride ≤4.5
mmol/L
GAUSS-2 2014 307 12 62 (10) 141 (46) 5.0 (1.5) NA 1.3 (0.5) 4.4 (1.7) 55 (18) NA NA 62 (20) LDL-C ≥ 2.6 mmol/L and
triglycerides ≤4.5 mmol/L. No/low-
dose statin or statin-intolerance




LDL-C ≥1.9 mmol/L and
triglycerides ≤4.5 mmol/L. Statin ±
ezetimibe

















From parent studies (RUTHERFORD,
LAPLACE-TIMI 57, GAUSS, MENDEL)
TESLA 2014 49 12 31 (13) 24 (49) 9.0 (3.5) NA 1.0 (0.3) 9.0 (2.7) 49 (100) 45 (92) 21 (43) NA Homozygous familial
hypercholesterolaemia, LDL-C ≥3.4
mmol/L. Statin ± ezetimibe
RUTHERFORD-2 2014 329 12 51 (14) 139 (42) 3.9 (1.0) NA 1.4 (0.4) 6.0 (1.7) 329 (100) 204 (62) 103
(31)
NA HeFH patients ≥2.6 mmol/L. Statin
± ezetimibe
McKenney 2012 183 12 57 (10) 96 (53) 3.4 (0.7) 5.4 (0.7) 1.3 (0.3) NA NA NA 10 (6) 22 (12) LDL-C ≥2.6 mmol/L on stable-dose
atorvastatin for ≥6 weeks
Stein 2012 77 12 53 (10) 30 (39) 3.9 (0.9) 6.1 (1.0) 1.4 (0.3) NA 77 (100) 55 (71) 32 (42) 3 (4) HeFH and LDL-C ≥2.6 mmol/L.
Statin ± ezetimibe
Roth 2012 92 8 57 (10) 55 (60) 3.2 (0.5) 5.2 (0.7) 1.4 (0.4) NA 92 (100) NA 3 (3) 14 (15) LDL-C ≥2.6 mmol/L on stable-dose
atorvastatin for ≥7 weeks
ODYSSEY
COMBO II




LDL-C ≥1.8 mmol/L (history of CVD)
or ≥2.6 mmol/L (no history of CVD)
High CV-risk patients on max-
tolerated statin
ODYSSEY FH I 2014 486 24 52 (12) 212 (55) 3.7 (1.2) NA NA NA 486 (100) 277 (57) 225
(46)
56 (12) HeFH, inadequately controlled on
maximally tolerated stable statin
therapy with or without other LLT
ODYSSEY FH II 2014 249 24 53 (13) 118 (47) 3.5 (1.1) NA NA NA 249 (100) 165 (66) 88 (35) 10 (4) HeFH, inadequately controlled on
maximally tolerated stable statin
therapy with or without other LLT
ODYSSEY LONG
TERM






HeFH or High-CV risk patients LDL-
C ≥1.8 mmol/L on max-tolerated
statin therapy with or without other
LLT
ODYSSEY MONO 2014 103 24 60 (5) 48 (47) 3.6 (0.6) 5.8 (0.8) 1.6 (0.5) NA 0 0 NA 4 (4) LDL-C ≥2.6 and <4.9 mmol/L, 10-year
risk of fatal cardiovascular events ≥1
% and ≤5 %
ODYSSEY
ALTERNATIVE
2014 251 24 63 (10) 114 (45) 5.0 (1.8) NA 1.3 (0.4) NA NA NA 118
(47)
60 (24) Statin intolerant patients (by
medical history) with LDL-C ≥70








High CV risk on maximally tolerated
statin with or without other LLT
(LDL-C ≥70 mg/dl manifest CVD; or
LDL-C ≥100 mg/dl with DM and
other risk factors or CKD)
ODYSSEY HIGH
FH
2014 107 24 52 (11) 50 (47) 5.2 (1.1) NA NA NA 107 (100) 26 (24) 53 (50) 15 (14) HeFH inadequately controlled on
maximally tolerated stable statin













Table 1 Baseline characteristics of included randomized trials (Continued)
ODYSSEY
OPTION I
2014 205 24 66 (9) 75 (36) 2.6 (0.8) NA NA NA 182 (100) NA NA NA Patients with prior CVD + LDL-C




2014 204 24 60 (10) 88 (43) 2.7 (1.1) NA NA NA 175 (100) NA NA NA Patients with prior CVD + LDL-C
≥70 mg/dl, or CV risk factors + LDL-
C ≥100 mg/dl
Data are mean (SD), mean (SE), number (%), or median (IQR); lipid profiles are mean (SE) if not indicated; age is mean (SD). DESCARTES, the Durable Effect of PCSK9 Antibody Compared with Placebo Study trial;
GAUSS, the Goal Achievement after Utilizing an anti-PCSK9 antibody in Statin Intolerant Subjects trial; LAPLACE-TIMI 57, the LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin
Therapy (LAPLACE)–Thrombolysis in Myocardial Infarction (TIMI) 57 trial; MENDEL, Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid
Levels trial; OSLER, the Open Label Study of Long Term Evaluation Against LDL-C trial; RUTHERFORD, The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder trial;
TESLA, The Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities; YUKAWA, the StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced
Cardiovascular Risk trial
CHD, coronary heart disease; CVD, cardiovascular disease; DM, diabetes mellitus; HDL-C, high-density lipoprotein (HDL) cholesterol; HeFH, heterozygous familial hypercholesterolemia IQR, interquartile range; LDL-C,












Zhang et al. BMC Medicine  (2015) 13:123 Page 7 of 18CI: 44.8 to 59.7 %) at 12 weeks follow-up, which was not
significantly different from placebo (pooled rate: 45.2 %;
95 % CI: 40.6 to 49.8 %) (relative risk (RR): 1.07, 95 % CI:
0.95 to 1.21) or ezetimibe (pooled rate: 54.7 %; 95 % CI:
41.3 to 68.0 %) (RR: 0.92, 95 % CI: 0.84 to 1.01, Table 2).
Serious TEAE occurred in 1.9 % patients, TEAEs leading
to discontinuation in 1.6% patients at 12 weeks following
evolocumab treatment. Only 1 in 3,068 patients died at 12
weeks follow-up and 3 in 1,335 patients at 52 weeks
follow-up, which were all similar to control groups
(Table 2). Sixteen in 2,797, 12 in 2,797, and 20 in 2,287 pa-
tients developed creatine kinase (CK) elevations greater
than five times the upper limit of normal (ULN), eleva-
tions in aspartate aminotransferase/alanine aminotransfer-
ase (AST/ALT) levels greater than three times the ULN,
and adjudicated cardiovascular events respectively. Pa-
tients receiving evolocumab had a lower risk of developing
abnormal liver function (AST/ALT greater than three
times ULN) than those receiving placebo at 12-week
follow-up (RR: 0.43, 95 % CI: 0.20 to 0.93, P = 0.03), but
the difference did not maintain at 52-week follow-up. The
pooled incidence of musculoskeletal and connective-tissue
disorders was 9.8 % (95 % CI: 4.1 to 15.4 %), which was
not significantly different with placebo (pooled rate: 7.1 %;
95 % CI: 1.6 to 12.6 %) (RR 1.08, 95 % CI: 0.70 to 1.67) or
ezetimibe (pooled rate: 6.1 %; 95% CI: 0.7 to 11.5 %) (RR
1.10, 95 % CI: 0.61 to 2.00). Injection-site reactions oc-
curred in 2.2 % of patients. No significant difference in
any reported adverse event was found between monthly
420 mg and biweekly 140 mg administration at 12 weeks
follow-up (Table 3). The event rates at 52-week follow-up
following evolocumab are also reported in Table 2.
Safety outcomes of alirocumab
Three phase 2 studies reported safety outcomes at 8 to
12 weeks, while other phase 3 studies reported either at
24-week or 52-week follow-up. Safety profiles were
pooled together in all trials. Any TEATs happened in
71.7 % (95 % CI: 67.7 to 75.6 %) patients following alirocu-
mab treatment, mirrored to those with placebo (68.4 %,
95 % CI: 58.7 to 76.2 %) (RR: 1.00, 95 % CI: 0.92 to 1.10)
or ezetimibe treatment (70.1 %, 95 % CI: 62.9 to 77.4 %)
(RR: 1.01, 95 % CI: 0.96 to 1.07, Table 4). TEAEs which
were serious or led to discontinuation occurred in 8.6 %
and 4.8 % of patients, respectively. Fifteen in 3,363, 11 in
992, and 7 in 862 died following alirocumab, placebo or
ezetimibe treatments, respectively, showing a lower rate in
alirocumab compared with placebo (RR: 0.43, 95 % CI:
0.19 to 0.96, P = 0.04), but not ezetimibe (RR: 0.48, 95 %
CI: 0.16 to 1.45, P = 0.19). CK greater than three times
ULN, ALT/AST greater than three times ULN, and
adjudicated cardiovascular events were detected in 2.0 %,
0.9 %, and 2.6 % of patients, respectively (Table 4). A trend
toward a lower rate of serum CK level elevation wasobserved in alirocumab group than placebo group (RR:
0.72, 95 % CI: 0.52 to 1.01, P = 0.06). Musculoskeletal and
connective-tissue disorders occurred in 16.7 % patients. A
higher rate of injection-site reactions was detected follow-
ing alirocumab administration (pooled rate: 6.0 %, 95 % CI:
3.8 to 8.2 %) than placebo (pooled rate: 3.7 %, 95 % CI: 2.5
to 4.8 %) (RR: 1.48, 95 % CI: 1.05 to 2.09, P = 0.02). Neuro-
cognitive disorders were observed in 0.6 % alirocumab-
treated patients. Still, all other reported adverse events
rates did not differ significantly between alirocumab and
placebo/ezetimibe treatments.
Primary efficacy outcomes of evolocumab
All six dosages of evolocumab significantly decreased
LDL-C level at 12 weeks follow-up, with the greatest re-
ductions achieved in monthly 420 mg evolocumab
(mean reduction: −54.6 %, 95 % CI: −58.7 to −50.5 %) and
biweekly 140 mg evolocumab (mean reduction: −60.4 %,
95 % CI: −68.8 to −52.0 %) versus placebo (Fig. 2 and
Additional file 2: Table S4). There was significant hetero-
geneity in both comparisons (I2 = 80.4 % and 93.9 %, re-
spectively). Biweekly administration of 140 mg evolocumab
led to even greater reduction than 420 mg monthly
treatment, both of which reduced the LDL-C level by
over 50 %. The effect is likely dose-dependent with the
same frequency of administration. Likewise, in absolute
level changes, 420 mg monthly and 140 mg biweekly
dosing lowered LDL-C by −78.9 mg/dl (95 % CI: −88.9
to −68.9 mg/dl) and −81.6 mg/dl (95 % CI: −92.0 to −71.1
mg/dl), respectively (Additional file 2: Figure S1 and
Table S4).
Compared with ezetimibe, significant lowering of LDL-C
also occurred in all evolocumab dosages at week 12.
Monthly 420 mg and biweekly 140 mg evolocumab admin-
istration reduced LDL-C level by −36.3 % (95 % CI: −38.8
to −33.9 %) and −38.2 % (95 % CI: −41.5 to −34.5 %), re-
spectively, versus ezetimibe (Fig. 3 and Additional file 2:
Table S4). No significant heterogeneity was detected in the
comparisons (I2 = 0 and 28.4 %, respectively). Fewer stud-
ies reported absolute changes of LDL-C level versus ezeti-
mibe; meta-analyses of these studies demonstrated largely
similar but less remarkable results compared with those
versus placebo.
LDL-C percent and absolute changes at the mean of
weeks 10 and 12 following evolocumab treatments ver-
sus placebo or ezetimibe were all significant and similar
to those changes at week 12 (Additional file 2: Table S5).
Other efficacy outcomes of evolocumab
All dosages except monthly 280 mg evolocumab treat-
ment significantly increased high-density lipoprotein
cholesterol (HDL-C) levels at week 12 compared with
placebo. The HDL-C level was increased by 7.6 % (95 %
CI: 5.7 to 9.5 %) and 6.9 % (95 % CI: 5.4 to 8.4 %) by
Table 2 Adverse event rates at 12- and 52-week follow-up following evolocumab, placebo or ezetimibe treatments
Safety endpoints Evolocumab (12 Week) Placebo (12 Week) Evolocumab versus Placebo
(12 Week)






Event/Total Pooled event rate
(95 % CI)
Event/Total RR (95 % CI) P value Pooled event rate
(95 % CI)
Event/Total RR (95 % CI) P value Event/Total
TEAE (Any) 52.2 (44.8, 59.7) 1472/3068 45.2 (40.6, 49.8) 534/1240 1.07 (0.95, 1.21) 0.260 54.7 (41.3, 68.0) 278/554 0.92 (0.84, 1.01) 0.074 78.4 (1047/1335)
TEAE (Serious) 1.9 (1.4, 2.4) 64/3068 1.2 (0.5, 1.9) 23/1240 0.96 (0.60, 1.55) 0.876 0.9 ( 0.3, 1.6) 7/554 1.35 (0.61, 3.00) 0.458 6.4 (85/1335)
Leading to
discontinuation
1.6 (0.9, 2.4) 56/3068 1.1 (0.4, 1.8) 21/1240 0.78 (0.46, 1.32) 0.354 3.5 (1.0, 6.0) 24/554 0.68 (0.42, 1.11) 0.127 3.0 (40/1335)
Death NA 1/3068 NA 1/1240 NA NA NA 0/554 NA NA 0.2 (3/1335)
CK >5 ULN 0.5 (0.1, 0.8) 16/2797 0.5 (0.2, 0.8) 8/1150 0.57 (0.21, 1.51) 0.258 0.5 (0, 0.8) 4/509 0.55 (0.17, 1.81) 0.325 1.0 (14/1335)
ALT or AST >
3 ULN








9.8 (4.1, 15.4) 144/1397 7.1 (1.6, 12.6) 39/508 1.08 (0.70, 1.67) 0.738 6.1 (0.7, 11.5) 13/231 1.10 (0.61, 2.00) 0.751 9.2 (68/736)
Back pain 2.6 (1.7, 3.4) 56/2208 1.8 (0.7, 2.8) 21/912 1.05 (0.53, 2.11) 0.883 2.5 (0.9, 4.1) 8/298 0.72 (0.34, 1.54) 0.4 6.4 (85/1335)
Arthralgia 1.7 (1.0, 2.5) 35/1862 1.7 (0.9, 2.6) 14/803 1.04 (0.56, 1.93) 0.912 1.5 (0.2, 2.9) 4/266 0.97 (0.35, 2.64) 0.945 5.7 (76/1335)
Muscle spasms 1.9 (0.7, 3.2) 45/2193 1.3 (0.5, 2.0) 11/803 1.02 (0.42, 2.49) 0.963 2.5 (0.7, 4.3) 13/400 0.67 (0.30, 1.50) 0.335 2.3 (14/599)
Myalgia 3.5 (1.5, 5.6) 48/1382 1.0 (0.2, 1.8) 5/399 1.13 (0.37, 3.43) 0.833 5.0 (0.6, 9.4) 23/333 0.68 (0.30, 1.56) 0.364 4.0 (24/599)
Headache 3.4 (2.2, 4.6) 86/2830 2.6 (1.5, 3.7) 34/1122 0.81 (0.53, 1.24) 0.331 2.8 (1.2, 4.4) 20/554 0.94 (0.57, 1.55) 0.798 4.0 (24/599)
Injection-site
reactions
2.2 (1.3, 3.1) 64/2831 1.7 (0.9, 2.5) 26/1184 1.06 (0.67, 1.67) 0.816 2.0 (0.4, 3.6) 13/522 1.02 (0.54, 1.93) 0.955 5.4 (72/1335)
Gastrointestinal
disorders
5.6 (2.7, 8.4) 118/1620 5.3 (1.9, 8.7) 33/580 1.09 (0.68, 1.75) 0.73 6.8 (0.1, 13.4) 18/301 0.81 (0.47, 1.39) 0.441 6.3 (38/599)
Nasopharyngitis 6.2 (3.6, 8.8) 115/1746 4.2 (2.1, 6.3) 28/580 1.39 (0.93, 2.08) 0.11 4.8 (1.6, 8.0) 18/333 0.54 (0.30, 1.15) 0.113 11.5 (153/1335)
Influenza 1.7 (0.5, 2.8) 27/1220 2.0 (0, 4.3) 9/317 0.89 (0.38, 2.07) 0.792 2.1 (0.1, 4.0) 5/179 0.34 (0.10, 1.18) 0.090 7.3 (97/1335)
Upper respiratory
tract infection
4.2 (2.5, 5.9) 43/1015 2.9 (0.3, 5.6) 12/317 1.01 (0.54, 1.90) 0.964 5.3 (0, 14.4) 5/77 0.74 (0.22, 2.50) 0.624 8.5 (113/1335)












Table 3 Adverse event rates at 12-week follow-up following different dosages of evolocumab treatments




Event/Total Pooled event rate
(95 % CI)
Event/Total RR (95 % CI) P value
TEAE (Any) 52.1 (42.9, 61.3) 565/1228 52.0 (43.1, 60.9) 496/1095 1.01 (0.92, 1.10) 0.873
TEAE (Serious) 1.4 (0.8, 1.9) 23/1228 2.5 (1.6, 3.3) 30/1095 0.69 (0.39, 1.23) 0.214
Leading to discontinuation 1.4 (0.6, 2.2) 26/1228 1.8 (0.8, 2.9) 26/1095 0.94 (0.54, 1.64) 0.835
Death NA 0/1228 NA 1/1095 NA NA
CK >5 ULN 0.5 (0.1, 0.9) 8/1183 0.1 (0, 0.3) 2/1050 1.58 (0.44, 5.75) 0.484
ALT or AST >3 ULN 0.4 (0.2, 0.7) 5/1183 0.5 (0.1, 0.8) 5/1050 0.70 (0.20, 2.44) 0.573
Adjudicated cardiovascular events 1.1 (0.2, 2.0) 3/288 1.5 (0.3, 2.6) 6/285 0.56 (0.17, 1.92) 0.36
Musculoskeletal and connective-tissue disorders 3.9 (1.0, 6.9) 21/421 8.0 (3.4, 12.5) 30/386 0.63 (0.29, 1.34) 0.227
Back pain 3.6 (1.0, 6.3) 20/830 2.4 (1.4, 3.5) 20/788 1.09 (0.42, 2.87) 0.86
Arthralgia 1.8 (0.9, 2.7) 13/687 1.5 (0.6, 2.3) 10/678 1.27 (0.56, 2.87) 0.568
Muscle spasms 2.0 (0.5, 3.5) 18/823 1.4 (0.4, 2.5) 15/780 1.10 (0.56, 2.20) 0.776
Myalgia 1.3 (0, 2.7) 11/414 2.3 (0.4, 4.2) 12/378 0.91 (0.40, 2.06) 0.82
Headache 3.1 (1.7, 4.4) 40/1142 2.7 (1.3, 4.2) 26/1043 1.40 (0.84, 2.33) 0.202
Injection-site reactions 2.0 (0.9, 3.1) 18/577 2.4 (0.8, 4.0) 19/540 0.94 (0.50, 1.78) 0.853
Gastrointestinal disorders 4.9 (2.3, 7.5) 35/580 5.4 (2.5, 8.2) 28/488 1.13 (0.68, 1.87) 0.637
Nasopharyngitis 4.9 (2.5, 7.4) 36/613 4.1 (1.7, 6.6) 24/488 1.10 (0.63, 1.89) 0.744
Influenza 1.2 (0.1, 2.4) 9/350 2.5 (0.4, 5.4) 8/225 0.19 (0.03, 1.10) 0.064
Upper respiratory tract infection 4.6 (2.2, 6.9) 14/247 4.8 (1.2, 8.4) 6/123 1.30 (0.46, 3.70) 0.621
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; CK, creatine kinase; NA, not applicable; RR, relative risk; TEAE, treatment
emergent adverse event; ULN, upper limit of normal
Zhang et al. BMC Medicine  (2015) 13:123 Page 9 of 18monthly 420 mg and biweekly 140 mg evolocumab treat-
ment, respectively (Fig. 4 and Additional file 2: Table S6).
No significant heterogeneity was detected in the compari-
sons (I2 = 23.3 % and 0, respectively). These two dosages
of evolocumab also increased the HDL-C level compared
with ezetimibe by 6.4 % (95 % CI: 4.3 to 8.4 %) and 7.2 %
(95 % CI: 4.4 to 10.0 %), with no significant heterogeneity
(I2 = 0 and 32.2 %, respectively).
Compared with placebo, all dosages of evolocumab gen-
erated significant reductions of total cholesterol (TC),
TC/HDL-C, non-HDL-C and very low-density lipopro-
tein cholesterol (VLDL-C), which were decreased by
monthly 420 mg evolocumab by −36.7 % (95 % CI: −38.9
to −34.4 %), −41.3 % (95 % CI: −45.7 to −36.9 %), −52.1 %
(95 % CI: −55.1 to −49.1 %), and −22.8 % (95 % CI: −27.5
to −18.0 %), respectively at week 12, with low to modest
levels of heterogeneity (I2 = 38.0 %, 64.7 %, 57.9 % and
6.6 %, respectively) (Table 5 and Additional file 2: Figures
S2 to S5, Tables S7 to S10). Similar results were detected
following biweekly 140 mg evolocumab treatment.
A significant increase in apolipoprotein A1 (ApoA1)
was found at week 12 in all dosages of evolocumab ex-
cept biweekly 105 mg administration. Monthly 420 mg
and biweekly 140 mg treatment increased the ApoA1
level by 5.2 % (95 % CI: 2.6 to 7.7 %) and 6.3 % (95 % CI:1.7 to 10.8 %) versus placebo, respectively (Table 5 and
Additional file 2: Figure S6 and Table S11).
All dosages of evolocumab significantly lowered apolipo-
protein B (ApoB), ApoB/ApoA1, and lipoprotein(a) (Lp(a))
at week 12, with monthly 420 mg treatment reducing levels
by −45.1 % (95 % CI: −49.2 to −41.1 %), −48.1 % (95 %
CI: −52.7 to −43.4 %), and −25.4 % (95 % CI: −29.1
to −21.7 %), respectively, versus placebo (Table 5 and
Additional file 2: Figure S7 to S9, Tables S12 to S14).
Modest to high levels of heterogeneity were found in
both comparisons (I2 = 78.9 %, 72.4 %, and 47.1 %,
respectively).
A significant decrease in triglycerides (TG) was found
at week 12 in all dosages of evolocumab except biweekly
105 mg administration. Monthly 420 mg and biweekly
140 mg treatments lowered the TG level by −15.7 % (95 %
CI: −20.4 to −11.1 %) and −17.4 % (95 % CI: −23.5
to −11.2 %) versus placebo, respectively (Table 5 and
Additional file 2: Figure S10 and Table S15). A modest
level of heterogeneity was detected.
The free PCSK9 level was decreased by any dosage of
evolocumab treatment. At week 12, monthly 420 mg and
biweekly 140 mg treatments lowered the PCSK9 level
by −44.0 % (95 % CI: −53.9 to −34.2 %) and −60.9 % (95 %
CI: −83.9 to −37.9 %) versus placebo, respectively (Table 5
Table 4 Adverse event rates following alirocumab, placebo or ezetimibe treatments
Safety endpoint Alirocumab Placebo Alirocumab versus Placebo Ezetimibe Alirocumab versus Ezetimibe
Pooled event rate
(95 % CI)
Event/Total Pooled event rate
(95 % CI)
Event/Total RR (95 % CI) P value Pooled event rate
(95 % CI)
Event/Total RR (95 % CI) P value
TEAE (Any) 71.7 (67.7, 75.6) 2561/3425 68.4 (58.7, 78.2) 783/1007 1.00 (0.92, 1.10) 0.938 70.1 (62.9, 77.4) 605/862 1.01 (0.96, 1.07) 0.615
TEAE (Serious) 8.6 (4.5, 12.8) 455/3363 9.3 (1.2, 17.4) 158/992 0.94 (0.79, 1.12) 0.47 8.5 (4.1, 12.8) 91/862 1.03 (0.81, 1.31) 0.815
Leading to discontinuation 4.8 (2.7, 6.9) 187/3363 4.6 (2.1, 7.1) 56/992 1.07 (0.78, 1.47) 0.667 7.9 (3.9, 12.0) 69/862 0.83 (0.38, 1.83) 0.645
Death 0.5 (0.3, 0.7) 15/3363 1.2 (0.5, 1.8) 11/992 0.43 (0.19, 0.96) 0.04 0.5 (0.1, 1.0) 7/862 0.48 (0.16, 1.45) 0.192
CK >3 ULN 2.0 (1.0, 3.1) 114/3415 3.9 (2.0, 5.8) 54/1003 0.72 (0.52, 1.01) 0.059 2.4 (1.1, 3.7) 28/855 0.75 (0.46, 1.24) 0.261
ALT or AST >3 ULN 0.9 (0.5, 1.3) 25/1869 1.3 (0.2, 2.4) 2/218 0.95 (0.26, 3.47) 0.94 0.5 (0.2, 0.9) 4/858 1.91 (0.75, 4.88) 0.176
Musculoskeletal and
connective-tissue disorders
16.7 (5.9, 27.6) 536/2450 17.3 (3.8, 30.7) 235/865 1.00 (0.87, 1.14) 0.967 22.3 (0, 46.5) 74/416 0.80 (0.60, 1.05) 0.108
Injection-site reactions 6.0 (3.8, 8.2) 225/3425 3.7 (2.5, 4.8) 42/1007 1.48 (1.05, 2.09) 0.024 3.0 (1.1, 4.9) 35/862 1.30 (0.88, 1.92) 0.194
Adjudicated cardiovascular events 2.6 (1.3, 3.9) 109/3130 3.2 (1.3, 5.0) 38/930 0.94 (0.64, 1.39) 0.768 1.2 (0.5, 1.9) 15/811 1.29 (0.71, 2.36) 0.405
Nervous system disorders 9.3 (4.2, 14.5) 338/2813 6.6 (0.0, 15.9) 145/865 0.97 (0.81, 1.17) 0.776 6.2 (4.2, 8.2) 34/536 0.85 (0.56, 1.30) 0.461
Gastrointestinal disorders 16.4 (9.4, 23.4) 332/1845 13.3 (5.1, 21.5) 158/865 1.01 (0.57, 1.80) 0.964 9.8 (1.6, 8.0) 5/51 1.77 (0.63, 4.91) 0.276
Neurocognitive disorders 0.6 (0.2, 1.1) 27/2923 0.6 (0.1, 1.0) 6/930 1.03 (0.23, 4.60) 0.97 1.3 (0.5, 2.1) 8/609 0.65 (0.22, 1.91) 0.431












Fig. 2 Pooled analysis for percent changes in LDL-C following evolocumab treatments stratified by dosages versus placebo at 12 weeks follow-
up. EVO, evolocumab; PBO, placebo. LDL-C, low-density lipoprotein cholesterol
Zhang et al. BMC Medicine  (2015) 13:123 Page 11 of 18and Additional file 2: Table S16). Significant heterogeneity
was detected.
Similar results were obtained at the mean of weeks 10
and 12, and largely similar but less remarkable results
were achieved when compared with ezetimibe (Additional
file 2). Two RCTs reported efficacy outcomes of monthly
420 mg treatment at 52 weeks follow-up. Likewise, all
the comparisons were significant (Additional file 2:
Figure S11).
Efficacy outcomes of alirocumab
Both monthly and biweekly administration of alirocumab
significantly lowered LDL-C levels, with biweekly 50 to
150 mg treatment reduced by over −50 % (mean reduc-
tion: −52.6 %, 95 % CI: −58.2 to −47.0 %) versus placebo, a
less marked reduction was achieved when compared with
ezetimibe (mean reduction: −29.9 %, 95 % CI: −32.9
to −26.9 %) and by monthly 150 to 300 mg treatment
versus placebo (mean reduction: −32.2 %, 95 % CI: −48.7
to −15.6 %). Significant heterogeneity was detected in
comparisons with placebo (Fig. 5A).HDL-C level was increased by 8.0 % (95 % CI: 4.2 to
11.7 %) following biweekly 50 to 150 mg treatment and
by 7.4 % (95 % CI: 3.8 to 11.1 %) after monthly 150 to
300 mg administration. No significant heterogeneity
was found (I2 = 0 for both comparisons) (Fig. 5B). Meta-
analyses of other efficiency outcomes demonstrated re-
duction in TC, non-HDL-C, ApoB, and Lp(a), and an
increase in ApoA1 following alirocumab treatment, which
are shown in Table S17 (in Additional file 2).
No significant publication bias was found in most
analyses, detailed in each table in Additional file 2. Sen-
sitivity analyses did not generated inconsistent results.
Discussion
For the first time we provide in our study the rates of
common adverse events following PCSK-9 antibody treat-
ments by enrolling the largest sample size of patients and
thus offering the most robust power, and detected largely
no significant difference in major adverse events rates be-
tween antibody administration and control treatment, and
no difference between different dosages of evolocumab.
Fig. 3 Pooled analysis for percent changes in LDL-C following evolocumab treatments stratified by dosages versus ezetimibe at 12 weeks follow-up.
EVO, evolocumab; EZE, ezetimibe. LDL-C, low-density lipoprotein cholesterol
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function, and alirocumab was associated with reduced
rates of death and abnormal kidney function. Meanwhile,
we determined the extent of LDL-C lowering of anti-
PCSK9 antibodies: LDL-C level was reduced by over 50 %
even though patients were on stable statin treatment. The
extents of other favorable lipids changes were also docu-
mented in our meta-analyses.
It is worth noting that the favorable effects of anti-
PCSK9 antibodies were largely achieved in populations
who were already on stable statin treatments, indicating
an additive, or even synergistic effect to statin in lower-
ing LDL-C levels. This is not a surprise because statin
therapy has been well documented to increase PCSK9
levels [40]; thus, inhibiting PCSK9 might enhance the
LDL-C lowering effects of statins. Indeed, missense mu-
tations in PCSK9 increased response to statin therapy in
unrelated hypocholesterolemic subjects and familial
hypercholesterolemia patients [41]. Likewise, in our
meta-analysis, the combination of anti-PCSK9 antibody
and statin resulted in a very high-intensity LDL-lowering
effect, which is recommended by the 2013 American
College of Cardiology (ACC)/AHA guideline suggesting
no LDL-C goals. Meta-analyses of RCTs on statins also
demonstrated that further reductions in LDL-C produce
definite further reductions in CVD events [42], even in
people at low risk of CVDs [43].
Two fundamental elements could lead to safety
concerns: firstly those due to monoclonal antibodyadministration and secondly due to achieving very low
LDL-C levels. We were unable to obtain the mean
LDL-C level at the end of antibody administration due
to lack of patient-level data in our study. However, esti-
mated lowest LDL-C levels from observations of each
study were less than 50 mg/dl, which was more remark-
able than those achieved in the recently presented
IMPROVE-IT trial (Improved reduction of outcomes:
vytorin efficacy international trial) [44]. A combination of
simvastatin and ezetimibe led to a mean LDL-C level as
low as 53.2 mg/dl at one-year follow-up in high-risk pa-
tients with acute coronary syndrome, but showed good
safety outcomes, indicating that an even lower level of
LDL-C might not result in safety concerns. This notion
was further confirmed by two recently published trials
with regard to both evolocumab and alirocumab, with a
longer follow-up of approximately 12 months [23, 45].
The OSLER trial, an extension trial of several phase 2 and
phase 3 parent trials (most of which were included in our
meta-analysis), showed similar rates of adverse events in
patients with LDL-C levels less than 40 mg/dl or less than
25 mg/dl as in those with higher LDL-C levels following
evolocumab treatment [45]. The full-term follow-up of
the ODYSSEY LONG TERM trial also revealed similar
frequency of adverse events among patients who had a
LDL-C level less than 25 mg/dl and those who did not
[23]. More straightforwardly in our meta-analysis, ad-
ministration of both anti-PCSK9 antibodies showed
promising safety profiles, except that administration of
Fig. 4 Pooled analysis for percent changes in HDL-C following evolocumab treatments stratified by dosages versus placebo at 12 weeks follow-up.
EVO, evolocumab; PBO, placebo. HDL-C, high-density lipoprotein cholesterol
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injection-site reactions.
Whether anti-PCSK9 antibody treatments could trans-
late into improved cardiovascular outcomes remains to
be confirmed. The ongoing FOURIER (NCT01764633)
and ODYSSEY OUTCOMES (NCT01663402) trials will
answer this question by assessing the effect of evolocu-
mab and alirocumab on major CVD events with about
five years follow-up. However, the probable clinical ben-
efits could be preliminarily inferred based on current
evidence: 1) anti-PCSK9 antibodies substantially reduced
LDL-C, non-HDL-C and ApoB levels, all of which are
positively associated with CVD events [46], and ‘a lower
LDL-C, a better outcome’ has been indicated not only in
the era of statins but also following combined use of sta-
tins and ezetimibe [44]; 2) anti-PCSK9 antibodies signifi-
cantly increased HDL-C and ApoA1 levels, which are
strongly associated with reduced CVD risk, even in pa-
tients achieving very low LDL-C [47]; 3) in the ARIC
study, loss-of-function PCSK9 mutations resulted in 28 %
(15 %) reduction in LDL-C, and 88 % (47 %) reduction inCHD risk in African-Americans (white people) [48]; com-
bined analyses in other cohort studies also generated 30 %
reduction in ischemic heart disease risk [49]; and 4) more
direct evidence from the longer-term follow-up results of
the OSLER and ODYSSEY LONG TERM trials, although
with a limitation of exploratory analysis, both of these tri-
als suggested that patients receiving anti-PCSK9 anti-
bodies had a significantly lower risk of major adverse
cardiovascular events, which is consistent with our study
showing alirocumab reduced the rates of death. Notably,
both trials demonstrated that the cumulative incidence
curves diverged progressively over time; therefore, a more
remarkable benefit might be expected given a longer-term
follow-up. Provided the exploratory nature of these trials,
the limited follow-up length and the small number of car-
diovascular events, results from ongoing FOURIER (over
27,500 high-risk patients with cardiovascular disease) and
ODYSSEY OUTCOMES trials (over 18,000 patients who
have experienced an acute coronary syndrome event 4 to
52 weeks prior to randomization) are urgently needed to
provide definite answers.





Test for overall effect Number of
studies
Number of individuals Heterogeneity Publication bias
Z P value Evolocumab Placebo I2 P value P_Begg P_Egger
TC 420 mg Q4W −36.66 (−38.93, −34.39) 31.60 0.000 6 539 825 38.0 % 0.153 1.000 0.980
140 mg Q2W −40.48 (−45.33, −35.62) 16.35 0.000 4 456 730 85.3 % 0.000 0.734 0.552
HDL-C 420 mg Q4W 7.58 (5.69, 9.46) 7.89 0.000 9 688 1121 23.3 % 0.236 1.000 0.843
140 mg Q2W 6.90 (5.37, 8.43) 8.84 0.000 6 586 993 0.0 % 0.551 0.133 0.030
Non-HDL-C 420 mg Q4W −52.11 (−55.07, −49.14) 34.42 0.000 8 672 1088 57.9 % 0.020 0.618 0.499
140 mg Q2W −56.07 (−61.67, −50.47) 19.62 0.000 6 586 993 89.0 % 0.000 0.452 0.616
TC/HDL-C 420 mg Q4W −41.26 (−45.65, −36.87) 18.43 0.000 6 317 374 64.7 % 0.015 0.566 0.302
140 mg Q2W −44.85 (−49.11, −40.59) 20.64 0.000 4 229 285 63.6 % 0.041 0.089 0.126
VLDL-C 420 mg Q4W −22.75 (−27.46, −18.04) 9.47 0.000 6 567 925 6.6 % 0.374 0.452 0.335
140 mg Q2W −24.83 (−38.29, −11.38) 3.62 0.000 4 480 831 82.3 % 0.001 0.734 0.462
ApoB 420 mg Q4W −45.14 (−49.16, −41.12) 22.00 0.000 9 688 1121 78.8 % 0.000 0.076 0.027
140 mg Q2W −52.69 (−57.40, −47.98) 21.91 0.000 6 586 993 85.6 % 0.000 0.707 0.450
ApoA1 420 mg Q4W 5.17 (2.60, 7.73) 3.95 0.000 6 317 374 40.6 % 0.135 0.566 0.517
140 mg Q2W 6.26 (1.71, 10.82) 2.69 0.007 4 230 285 74.5 % 0.008 0.308 0.129
ApoB/ApoA1 420 mg Q4W −48.06 (−52.70, −43.43) 20.32 0.000 7 395 527 72.4 % 0.001 0.649 0.351
140 mg Q2W −53.68 (−57.77, −49.59) 25.74 0.000 5 305 438 65.8 % 0.020 0.806 0.500
TG 420 mg Q4W −15.70 (−20.35, −11.05) 6.62 0.000 9 688 1121 42.5 % 0.084 0.118 0.030
140 mg Q2W −17.35 (−23.50, −11.20) 5.53 0.000 6 586 993 59.8 % 0.029 1.000 0.039
Lp(a) 420 mg Q4W −25.40 (−29.09, −21.70) 13.47 0.000 9 688 1121 47.1 % 0.057 1.000 0.626
140 mg Q2W −32.39 (−38.92, −25.87) 9.73 0.000 6 586 993 79.3 % 0.000 1.000 0.819
PCSK9 420 mg Q4W −44.04 (−53.90, −34.17) 8.75 0.000 6 540 908 85.2 % 0.000 0.452 0.473
140 mg Q2W −60.92 (−83.94, −37.89) 5.18 0.000 2 132 188 92.9 % 0.000 1.000 NA
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoB/ApoA1, ratio of ApoB/ApoA1; CI, confidence interval; HDL-C, high-density lipoprotein (HDL) cholesterol; Lp(a), lipoprotein(a); NA, not applicable; Non-HDL-C,
non-HDL cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; TC, total cholesterol; TC/HDL-C,












Fig. 5 Pooled analysis for percent changes in LDL-C (a) and HDL-C (b) following alirocumab treatments stratified by dosages versus placebo or
ezetimibe. ALIR, alirocumab; EZE, ezetimibe; PBO, placebo. HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol
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First, the meta-analysis was based on study-level instead
of patient-level data. Second, a high level of heterogen-
eity exists in several analyses. Heterogeneities in patient
profile (unrelated or familial hypercholesterolemia) and
background lipid-lowering therapy (maximum-tolerated
statin, statin-intolerance, or no background anti-lipid
therapy) are likely to account for part of this heterogen-
eity. We performed subgroup analyses based on the type
of study population and heterogeneity still existed (data
not show). Therefore, we pooled these data with random-
effects models. Third, additional ongoing trials evaluating
the efficacy and safety of alirocumab are to be published
in a few years. However, with respect to primary efficacy
endpoint, dramatic upregulating-LDL effects needed to be
reported to balance the lowering-LDL effects demon-
strated in our study given the number of patients known
to have participated in these ongoing trials (ODYSSEY
CHOICE I, ODYSSEY OLE, and so on), which is unlikely.Fourth, with respect to analysis on safety profiles, wide-
range 95 % CIs were observed in several endpoints, which
made precise estimation of the incidences of these end-
points impossible. Meanwhile, several composite end-
points were included in our study, such as adjudicated
cardiovascular events, which might lower the ability of de-
tecting each individual endpoint. Fifth, most trials in-
cluded in our study had a relatively short-term follow-up
(12 and 52 weeks for evolocumab, and mostly 24 weeks
for alirocumab), thus rare events could not be fully re-
vealed. Sixth, we could not rule out bias of selective
reporting on several safety outcomes; to minimize this
bias, we reviewed all the materials (including supplemen-
tary materials and relevant publications in other papers)
provided by these studies and extracted and analyzed all
these data. Notably, no obvious selective reporting bias
was detected in major safety endpoints, such as any
TEAEs, serious TEAEs, abnormal liver function, abnormal
kidney function, injection-site reactions, musculoskeletal
Zhang et al. BMC Medicine  (2015) 13:123 Page 16 of 18disorders and so on. Seventh, most patients enrolled are
white; therefore, caution should be taken to interpret in
other populations.
Conclusions
Evolocumab and alirocumab were safe and well-tolerated,
largely showing no significant differences in rates of com-
mon adverse events with placebo or ezetimibe controls.
No difference was detected following different dosages of
evolocumab treatments regarding safety profiles. Both
anti-PCSK9 antibodies substantially reduced LDL-C by
over 50 %, increased HDL-C levels, and resulted in favor-
able changes in other lipids. We await the results of on-
going trials evaluating their effects on CVD events.
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